These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Infectious Agents as Potential Drivers of α-Synucleinopathies. Linard M; Ravier A; Mougué L; Grgurina I; Boutillier AL; Foubert-Samier A; Blanc F; Helmer C Mov Disord; 2022 Mar; 37(3):464-477. PubMed ID: 35040520 [TBL] [Abstract][Full Text] [Related]
45. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088 [TBL] [Abstract][Full Text] [Related]
46. An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. Serratos IN; Hernández-Pérez E; Campos C; Aschner M; Santamaría A Mol Neurobiol; 2022 Jan; 59(1):620-642. PubMed ID: 34750787 [TBL] [Abstract][Full Text] [Related]
47. The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates. Neupane S; De Cecco E; Aguzzi A J Mol Biol; 2023 Jun; 435(12):167930. PubMed ID: 36566800 [TBL] [Abstract][Full Text] [Related]
48. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy. Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358 [TBL] [Abstract][Full Text] [Related]
49. Parkinson's disease and other alpha-synucleinopathies. Goedert M Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653 [TBL] [Abstract][Full Text] [Related]
50. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy? De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639 [TBL] [Abstract][Full Text] [Related]
51. Structures of α-synuclein filaments from multiple system atrophy. Schweighauser M; Shi Y; Tarutani A; Kametani F; Murzin AG; Ghetti B; Matsubara T; Tomita T; Ando T; Hasegawa K; Murayama S; Yoshida M; Hasegawa M; Scheres SHW; Goedert M Nature; 2020 Sep; 585(7825):464-469. PubMed ID: 32461689 [TBL] [Abstract][Full Text] [Related]
52. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825 [TBL] [Abstract][Full Text] [Related]
53. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics. Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174 [TBL] [Abstract][Full Text] [Related]